-
Professor Lei Fan: Prospects for Treatment Strategies in Richter’s Transformation丨2024 Nanjing Lymphoma Forum
Hematology Frontier: The 2024 Nanjing Lymphoma Forum has arrived as scheduled. As one of the executive chairs, could you introduce this year’s meeting arrangements and highlight content? Professor Lei Fan:…
-
ASCO China Voice | Prof. Yijun Shen: Intravesical PD-1 Therapy Shows Promise for High-Risk NMIBC
Oncology Frontier: What are the unmet treatment needs for high-risk NMIBC patients? Professor Yijun Shen: NMIBC has always been a focus and challenge in bladder cancer diagnosis and treatment. These…
-
3rd SPCRIS | Prof. Yang Yu: Personalized Adjuvant Therapy in HR+/HER2− Early-Stage Breast Cancer
1. Balancing Survival Benefits and Quality of Life in Extended Endocrine Therapy Oncology Frontier: Extending endocrine therapy can provide survival benefits for patients with HR+/HER2− early breast cancer, but it…
-
2025 BOC/BOA | Prof. Zhi Peng Interprets DG-04 Study: New Evidence-Based Advances in HER2 ADCs Reshape Second-Line Treatment for HER2-Positive Advance
01 Oncology Frontier: Chemotherapy, immunotherapy, and anti-HER2 regimens have formed the backbone of first-line treatment for advanced gastric cancer. However, what unmet clinical needs remain in second- and later-line treatment…
-
Prof. Xichun Hu: Two Decades of China’s Breast Cancer Research — From Imitation to Innovation, Eastern Wisdom Shines on the Global Stage
Editor’s Note: Over the past two decades, clinical research on breast cancer in China has achieved a remarkable transformation — from “following” international standards to “running alongside”, and even “leading”…
-
Global Quality, Chinese Evidence | Prof. Jing Cheng: Lerociclib Achieves Continuous Target Inhibition with Balanced Efficacy and Safety
01 Oncology Frontier: With Lerociclib now approved in China, what impact will it have on the treatment of HR+/HER2– advanced breast cancer? Prof. Jing Cheng: For adult patients with HR+/HER2–…
-
Global Quality, Chinese Evidence | Prof. Xichun Hu: Lerociclib Approved by NMPA, Advancing HR+/HER2– Breast Cancer Care
Editor’s Note: As a standard treatment for hormone receptor–positive, HER2–negative metastatic breast cancer (HR+/HER2- MBC), CDK4/6 inhibitors (CDK4/6i) have significantly improved therapeutic outcomes and expanded treatment options. However, developing next-generation…
-
Global Quality, Chinese Evidence | Prof. Jianghua Ou on Lerociclib: Optimizing CDK4/6 Inhibitors for Broader Patient Benefit
Editor’s Note: CDK4/6 inhibitors (CDK4/6i) have become an important therapeutic option for hormone receptor–positive, HER2–negative (HR+/HER2-) breast cancer, yet there remains room for improvement in efficacy and safety. Recently, the…
Connecting Medical Expertise through Media